Market Exclusive

Arbutus Biopharma Corp (NASDAQ:ABUS) gets downgraded to Neutral by Chardan Capital

Analyst Ratings For Arbutus Biopharma Corp (NASDAQ:ABUS)

Today, Arbutus Biopharma Corp (NASDAQ:ABUS) stock was downgraded by Chardan Capital from Buy to Neutral.

There are 4 Hold Ratings, 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Arbutus Biopharma Corp (NASDAQ:ABUS) is Hold with a consensus target price of $6.33 per share, a potential 342.89% upside.

Some recent analyst ratings include

Recent Trading Activity for Arbutus Biopharma Corp (NASDAQ:ABUS)
Shares of Arbutus Biopharma Corp closed the previous trading session at 1.43 up +0.050 3.62% with 1.43 shares trading hands.

Exit mobile version